Focus: De Novo Pharmatech is a Shanghai-based biotech focused on small molecules and antibodies targeting oncology. The company is in early-stage development with a minimal pipeline presence.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow De Novo Pharmatech to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for De Novo Pharmatech
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from De Novo Pharmatech's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Active facility closure is a red flag for job security; further clarification on whether this reflects a strategic pivot or cash constraints is essential before applying.